Overview

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term (> 6 months) safety of PCI 24781 PO in subjects with lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmacyclics LLC.
Treatments:
Abexinostat
Histone Deacetylase Inhibitors